OTCMKTS:DSRLF

DiaSorin Competitors

$165.82
+0.82 (+0.49 %)
(As of 04/9/2021 10:07 PM ET)
Add
Compare
Today's Range
$165.82
Now: $165.82
$165.82
50-Day Range
$165.00
MA: $190.74
$219.00
52-Week Range
$0.00
Now: $165.82
$232.00
Volume100 shs
Average Volume294 shs
Market Capitalization$9.28 billion
P/E Ratio46.19
Dividend YieldN/A
Beta0.59

Competitors

DiaSorin (OTCMKTS:DSRLF) Vs. SDVKY, KHNGY, SVNDY, HNNMY, JAPAY, and EXPGY

Should you be buying DSRLF stock or one of its competitors? Companies in the industry of "private households" are considered alternatives and competitors to DiaSorin, including Sandvik AB (publ) (SDVKY), Kuehne + Nagel International (KHNGY), Seven & i (SVNDY), H & M Hennes & Mauritz AB (publ) (HNNMY), Japan Tobacco (JAPAY), and Experian (EXPGY).

DiaSorin (OTCMKTS:DSRLF) and Sandvik AB (publ) (OTCMKTS:SDVKY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Profitability

This table compares DiaSorin and Sandvik AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DiaSorinN/AN/AN/A
Sandvik AB (publ)6.75%19.81%10.54%

Earnings and Valuation

This table compares DiaSorin and Sandvik AB (publ)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiaSorin$791.17 million11.73$196.82 million$3.5946.19
Sandvik AB (publ)$10.92 billion3.29$903.43 million$1.1824.25

Sandvik AB (publ) has higher revenue and earnings than DiaSorin. Sandvik AB (publ) is trading at a lower price-to-earnings ratio than DiaSorin, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

0.1% of Sandvik AB (publ) shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for DiaSorin and Sandvik AB (publ), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DiaSorin41101.50
Sandvik AB (publ)321102.50

Volatility & Risk

DiaSorin has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Sandvik AB (publ) has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.

Summary

Sandvik AB (publ) beats DiaSorin on 10 of the 12 factors compared between the two stocks.

DiaSorin (OTCMKTS:DSRLF) and Kuehne + Nagel International (OTCMKTS:KHNGY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Profitability

This table compares DiaSorin and Kuehne + Nagel International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DiaSorinN/AN/AN/A
Kuehne + Nagel International3.88%34.26%8.27%

Valuation and Earnings

This table compares DiaSorin and Kuehne + Nagel International's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiaSorin$791.17 million11.73$196.82 million$3.5946.19
Kuehne + Nagel International$21.23 billion1.68$803.19 million$1.3444.51

Kuehne + Nagel International has higher revenue and earnings than DiaSorin. Kuehne + Nagel International is trading at a lower price-to-earnings ratio than DiaSorin, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for DiaSorin and Kuehne + Nagel International, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DiaSorin41101.50
Kuehne + Nagel International55001.50

Risk & Volatility

DiaSorin has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Kuehne + Nagel International has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.

Summary

Kuehne + Nagel International beats DiaSorin on 6 of the 10 factors compared between the two stocks.

DiaSorin (OTCMKTS:DSRLF) and Seven & i (OTCMKTS:SVNDY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Profitability

This table compares DiaSorin and Seven & i's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DiaSorinN/AN/AN/A
Seven & i3.02%9.95%4.43%

Valuation and Earnings

This table compares DiaSorin and Seven & i's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiaSorin$791.17 million11.73$196.82 million$3.5946.19
Seven & i$61.13 billion0.57$2.01 billion$1.5113.10

Seven & i has higher revenue and earnings than DiaSorin. Seven & i is trading at a lower price-to-earnings ratio than DiaSorin, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

0.1% of Seven & i shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for DiaSorin and Seven & i, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DiaSorin41101.50
Seven & i00103.00

Risk and Volatility

DiaSorin has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Seven & i has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.

Summary

Seven & i beats DiaSorin on 7 of the 11 factors compared between the two stocks.

DiaSorin (OTCMKTS:DSRLF) and H & M Hennes & Mauritz AB (publ) (OTCMKTS:HNNMY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Profitability

This table compares DiaSorin and H & M Hennes & Mauritz AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DiaSorinN/AN/AN/A
H & M Hennes & Mauritz AB (publ)1.62%5.72%1.87%

Valuation and Earnings

This table compares DiaSorin and H & M Hennes & Mauritz AB (publ)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiaSorin$791.17 million11.73$196.82 million$3.5946.19
H & M Hennes & Mauritz AB (publ)$24.63 billion1.38$1.43 billion$0.1727.35

H & M Hennes & Mauritz AB (publ) has higher revenue and earnings than DiaSorin. H & M Hennes & Mauritz AB (publ) is trading at a lower price-to-earnings ratio than DiaSorin, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

0.0% of H & M Hennes & Mauritz AB (publ) shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for DiaSorin and H & M Hennes & Mauritz AB (publ), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DiaSorin41101.50
H & M Hennes & Mauritz AB (publ)36502.14

Risk and Volatility

DiaSorin has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, H & M Hennes & Mauritz AB (publ) has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500.

Summary

H & M Hennes & Mauritz AB (publ) beats DiaSorin on 10 of the 12 factors compared between the two stocks.

DiaSorin (OTCMKTS:DSRLF) and Japan Tobacco (OTCMKTS:JAPAY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Profitability

This table compares DiaSorin and Japan Tobacco's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DiaSorinN/AN/AN/A
Japan Tobacco13.61%11.20%5.45%

Valuation and Earnings

This table compares DiaSorin and Japan Tobacco's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiaSorin$791.17 million11.73$196.82 million$3.5946.19
Japan Tobacco$19.96 billion1.68$3.20 billion$0.9010.50

Japan Tobacco has higher revenue and earnings than DiaSorin. Japan Tobacco is trading at a lower price-to-earnings ratio than DiaSorin, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

0.1% of Japan Tobacco shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for DiaSorin and Japan Tobacco, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DiaSorin41101.50
Japan Tobacco01002.00

Risk and Volatility

DiaSorin has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Japan Tobacco has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.

Summary

Japan Tobacco beats DiaSorin on 7 of the 12 factors compared between the two stocks.

DiaSorin (OTCMKTS:DSRLF) and Experian (OTCMKTS:EXPGY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Profitability

This table compares DiaSorin and Experian's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DiaSorinN/AN/AN/A
ExperianN/AN/AN/A

Valuation and Earnings

This table compares DiaSorin and Experian's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiaSorin$791.17 million11.73$196.82 million$3.5946.19
Experian$5.18 billion6.46$675 million$1.0235.75

Experian has higher revenue and earnings than DiaSorin. Experian is trading at a lower price-to-earnings ratio than DiaSorin, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

0.5% of Experian shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for DiaSorin and Experian, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DiaSorin41101.50
Experian02802.80

Risk and Volatility

DiaSorin has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Experian has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Summary

Experian beats DiaSorin on 6 of the 9 factors compared between the two stocks.


DiaSorin Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sandvik AB (publ) logo
SDVKY
Sandvik AB (publ)
0.8$28.62+1.3%$35.90 billion$10.92 billion54.00Upcoming Earnings
Kuehne + Nagel International logo
KHNGY
Kuehne + Nagel International
0.9$59.64+1.2%$35.70 billion$21.23 billion44.18
Seven & i logo
SVNDY
Seven & i
1.6$19.78+3.7%$34.99 billion$61.13 billion21.04
H & M Hennes & Mauritz AB (publ) logo
HNNMY
H & M Hennes & Mauritz AB (publ)
0.7$4.65+0.6%$33.96 billion$24.63 billion155.00Upcoming Earnings
Japan Tobacco logo
JAPAY
Japan Tobacco
1.2$9.45+1.0%$33.52 billion$19.96 billion12.43
Experian logo
EXPGY
Experian
1.1$36.46+0.0%$33.45 billion$5.18 billion35.75High Trading Volume
Techtronic Industries logo
TTNDY
Techtronic Industries
0.2$89.93+1.5%$32.97 billion$7.67 billion0.00
ASSA ABLOY AB (publ) logo
ASAZY
ASSA ABLOY AB (publ)
1.2$15.16+1.3%$31.99 billion$9.95 billion36.98
Amadeus IT Group logo
AMADY
Amadeus IT Group
0.5$70.47+2.4%$31.75 billion$6.25 billion-242.99
CK Hutchison logo
CKHUY
CK Hutchison
0.7$8.07+0.7%$31.12 billion$38.34 billion0.00
Swire Pacific logo
SWRAY
Swire Pacific
1.6$7.98+4.1%$31.00 billion$10.93 billion3.18Gap Down
Fujitsu logo
FJTSY
Fujitsu
0.9$30.59+0.1%$31.00 billion$35.49 billion23.17Gap Up
Ashtead Group logo
ASHTY
Ashtead Group
1.2$256.00+2.8%$28.76 billion$5.84 billion35.36
Associated British Foods logo
ASBFY
Associated British Foods
0.9$34.11+0.4%$27.00 billion$18.00 billion32.48
Sampo Oyj logo
SAXPY
Sampo Oyj
0.8$24.07+0.7%$26.96 billion$12.62 billion18.80
Zalando logo
ZLNDY
Zalando
0.4$52.13+0.2%$26.61 billion$7.26 billion236.97Analyst Upgrade
Compagnie Générale des Établissements Michelin Société en commandite par actions logo
MGDDY
Compagnie Générale des Établissements Michelin Société en commandite par actions
1.5$29.77+0.9%$26.55 billion$27.03 billion13.72Analyst Downgrade
Wilmar International logo
WLMIY
Wilmar International
0.7$40.85+0.3%$25.80 billion$42.64 billion20.02
Sunny Optical Technology (Group) logo
SNPTF
Sunny Optical Technology (Group)
0.5$22.95+3.8%$25.17 billion$5.48 billion0.00Gap Up
Unicharm logo
UNICY
Unicharm
0.9$8.36+1.2%$24.83 billion$6.55 billion64.31Gap Down
UniCredit logo
UNCFF
UniCredit
1.2$10.62+2.1%$23.79 billion$25.52 billion11.06Gap Up
Kerry Group logo
KRYAY
Kerry Group
1.2$134.26+0.1%$23.73 billion$8.11 billion30.44
BAE Systems logo
BAESY
BAE Systems
1.4$28.57+2.0%$23.00 billion$22.52 billion14.00Dividend Increase
Analyst Downgrade
China CITIC Bank logo
CHCJY
China CITIC Bank
0.9$9.38+0.4%$22.95 billion$47.62 billion0.00
SGS logo
SGSOY
SGS
1.3$29.89+0.6%$22.61 billion$6.64 billion33.58
CIADY
China Mengniu Dairy
0.9$56.84+3.2%$22.44 billion$11.44 billion37.39Gap Up
Shimano logo
SMNNY
Shimano
0.5$24.20+0.6%$22.43 billion$3.33 billion41.84
Ocado Group logo
OCDDY
Ocado Group
0.4$59.57+0.5%$22.30 billion$2.26 billion-78.38
Suzuki Motor logo
SZKMY
Suzuki Motor
1.5$176.87+1.5%$21.71 billion$32.03 billion20.98Analyst Downgrade
Gap Up
Sysmex logo
SSMXY
Sysmex
0.6$51.10+1.1%$21.40 billion$2.78 billion77.42
Secom logo
SOMLY
Secom
1.3$21.39+1.0%$19.96 billion$9.75 billion26.09News Coverage
Sino Biopharmaceutical logo
SBMFF
Sino Biopharmaceutical
0.8$1.06+0.5%$19.92 billion$3.51 billion0.00Gap Up
Eisai logo
ESALY
Eisai
1.3$67.14+1.2%$19.91 billion$6.40 billion17.35
Nomura Research Institute logo
NRILY
Nomura Research Institute
1.1$30.81+1.9%$19.74 billion$4.87 billion36.25
Ferrovial logo
FRRVY
Ferrovial
0.5$26.51+0.5%$19.43 billion$6.78 billion0.00
Eurofins Scientific logo
ERFSF
Eurofins Scientific
0.9$102.00+0.6%$18.16 billion$5.19 billion45.13
OMRON logo
OMRNY
OMRON
1.0$84.41+0.4%$17.41 billion$6.24 billion0.00
Deutsche Wohnen logo
DWHHF
Deutsche Wohnen
0.9$48.28+89.5%$17.37 billion$937.88 million14.12Gap Up
Rakuten logo
RKUNY
Rakuten
0.6$12.06+0.2%$17.33 billion$11.60 billion-19.77
Chow Tai Fook Jewellery Group logo
CJEWY
Chow Tai Fook Jewellery Group
1.2$16.89+0.1%$16.89 billion$7.26 billion45.65
OMV Aktiengesellschaft logo
OMVJF
OMV Aktiengesellschaft
1.0$51.22+0.3%$16.72 billion$26.28 billion-51.74
NN Group logo
NNGRY
NN Group
1.1$25.23+0.2%$16.67 billion$22.92 billion7.84
COSCO SHIPPING logo
CICOY
COSCO SHIPPING
0.8$8.15+3.7%$16.65 billion$21.78 billion101.88High Trading Volume
Gap Up
Atlantia logo
ATASY
Atlantia
0.6$9.72+0.2%$16.05 billion$14.13 billion108.00
Surgutneftegas Public Joint Stock logo
SGTZY
Surgutneftegas Public Joint Stock
0.1$4.40+0.9%$15.72 billion$28.13 billion0.00
bioMérieux logo
BMXMF
bioMérieux
0.5$132.00+2.1%$15.62 billion$3.00 billion51.16Gap Down
Terna - Rete Elettrica Nazionale Società per Azioni logo
TEZNY
Terna - Rete Elettrica Nazionale Società per Azioni
0.6$21.90+1.5%$14.67 billionN/A0.00News Coverage
Gap Up
Carrefour logo
CRRFY
Carrefour
1.1$3.58+2.0%$14.64 billion$81.09 billion13.77Gap Up
Schroders logo
SHNWF
Schroders
0.9$51.20+7.6%$14.46 billion$3.24 billion20.24Gap Down
Persimmon logo
PSMMY
Persimmon
1.3$90.19+2.7%$14.39 billion$4.66 billion13.13Gap Down
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.